Weiren Xu

1.8k total citations
98 papers, 1.5k citations indexed

About

Weiren Xu is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Weiren Xu has authored 98 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 31 papers in Organic Chemistry and 22 papers in Oncology. Recurrent topics in Weiren Xu's work include Peroxisome Proliferator-Activated Receptors (15 papers), Diabetes Treatment and Management (11 papers) and Synthesis and biological activity (10 papers). Weiren Xu is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (15 papers), Diabetes Treatment and Management (11 papers) and Synthesis and biological activity (10 papers). Weiren Xu collaborates with scholars based in China, United States and United Kingdom. Weiren Xu's co-authors include Run‐Ling Wang, Shuqing Wang, Tang Li-da, Kuo‐Chen Chou, Fancui Meng, Ying Ma, Xian‐Chao Cheng, Jianwu Wang, Guilong Zhao and Xuyuan Liu and has published in prestigious journals such as PLoS ONE, Hepatology and Journal of Medicinal Chemistry.

In The Last Decade

Weiren Xu

95 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weiren Xu China 22 902 332 315 205 187 98 1.5k
Raman Sharma United States 27 785 0.9× 413 1.2× 208 0.7× 284 1.4× 126 0.7× 74 2.0k
Maria Giovanna Chini Italy 26 1.0k 1.2× 526 1.6× 411 1.3× 207 1.0× 208 1.1× 86 2.2k
Valentina Sepe Italy 26 638 0.7× 356 1.1× 713 2.3× 113 0.6× 367 2.0× 72 1.9k
Onat Kadioglu Germany 26 1.1k 1.2× 175 0.5× 486 1.5× 216 1.1× 64 0.3× 63 2.0k
Tatu Pantsar Finland 13 947 1.0× 204 0.6× 250 0.8× 401 2.0× 61 0.3× 28 1.6k
Dennis Dean United States 25 614 0.7× 571 1.7× 381 1.2× 126 0.6× 146 0.8× 66 2.0k
Lushan Yu China 26 1.4k 1.5× 152 0.5× 690 2.2× 176 0.9× 141 0.8× 132 2.8k
Nan Ma China 20 825 0.9× 361 1.1× 287 0.9× 99 0.5× 61 0.3× 90 1.7k
Karl‐Heinz Baringhaus Germany 21 800 0.9× 237 0.7× 464 1.5× 393 1.9× 185 1.0× 38 1.6k

Countries citing papers authored by Weiren Xu

Since Specialization
Citations

This map shows the geographic impact of Weiren Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiren Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiren Xu more than expected).

Fields of papers citing papers by Weiren Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiren Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiren Xu. The network helps show where Weiren Xu may publish in the future.

Co-authorship network of co-authors of Weiren Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Weiren Xu. A scholar is included among the top collaborators of Weiren Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiren Xu. Weiren Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feng, Xiao‐Yan, et al.. (2020). In-silico identification of peroxisome proliferator-activated receptor (PPAR)α/γ agonists from Ligand Expo Components database. Journal of Biomolecular Structure and Dynamics. 39(5). 1853–1864. 8 indexed citations
2.
Xiang, Qian, Nan Zhao, Chuan Li, et al.. (2019). The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. Asian Journal of Pharmaceutical Sciences. 15(2). 264–272. 7 indexed citations
3.
Yang, Qing‐Qing, Jing Sun, Chuan Li, et al.. (2019). Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 174. 479–485. 5 indexed citations
4.
He, Lingli, Chuan Li, Xuyuan Liu, et al.. (2017). Comparative study on the interaction between 3 CYP2C9 allelic isoforms and benzbromarone by using LC–MS/MS method. Journal of Chromatography B. 1070. 97–103. 4 indexed citations
5.
Wang, Meiyan, Yuanyuan Jin, Lisong Zhang, et al.. (2015). Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors. European Journal of Medicinal Chemistry. 103. 91–104. 26 indexed citations
6.
Zhang, Yazhou, Yuou Teng, Ying Ma, et al.. (2015). Design, synthesis and docking study of novel tetracyclic oxindole derivatives as α-glucosidase inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(7). 1471–1475. 20 indexed citations
7.
Ma, Ying, Xuejiao Wang, Yuanyuan Jin, et al.. (2014). Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach. Protein and Peptide Letters. 21(6). 556–563. 11 indexed citations
8.
Liu, Peng, et al.. (2013). Determination of dabigatran in rat plasma by HPLC. Zhongguo xin yao zazhi. 22(10). 1206–1209. 2 indexed citations
9.
Zha, Weibin, Guangji Wang, Weiren Xu, et al.. (2013). Inhibition of P-Glycoprotein by HIV Protease Inhibitors Increases Intracellular Accumulation of Berberine in Murine and Human Macrophages. PLoS ONE. 8(1). e54349–e54349. 32 indexed citations
10.
Li, Ying, Tang Li-da, Weiren Xu, et al.. (2012). Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo. Diabetes Research and Clinical Practice. 96(3). 362–370. 1 indexed citations
11.
Ma, Ying, Shuqing Wang, Weiren Xu, Run‐Ling Wang, & Kuo‐Chen Chou. (2012). Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach. PLoS ONE. 7(6). e38546–e38546. 98 indexed citations
12.
Zhang, Lisong, Shuqing Wang, Weiren Xu, Run‐Ling Wang, & Jingfang Wang. (2012). Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors. PLoS ONE. 7(10). e48453–e48453. 13 indexed citations
13.
Li, Ying, Xin Li, Xuemin Zheng, et al.. (2011). Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1. Peptides. 32(7). 1400–1407. 16 indexed citations
14.
Zhang, Datong, et al.. (2011). Synthesis and cytotoxic activity of novel 3-(1H-indol-3-yl)-1H-pyrazole-5-carbohydrazide derivatives. European Journal of Medicinal Chemistry. 46(12). 5868–5877. 35 indexed citations
15.
Zheng, Xuemin, Ying Li, Xin Li, et al.. (2011). Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice. 93(3). 410–420. 4 indexed citations
16.
Zhang, Datong, et al.. (2010). Synthesis and preliminary antibacterial evaluation of 2-butyl succinate-based hydroxamate derivatives containing isoxazole rings. Archives of Pharmacal Research. 33(6). 831–842. 27 indexed citations
17.
Wang, Wei‐Ting, et al.. (2009). Effects of Astragaloside IV on heart failure in rats. Chinese Medicine. 4(1). 6–6. 51 indexed citations
18.
Zhang, Datong, et al.. (2008). Design, synthesis and antibacterial activity of novel actinonin derivatives containing benzimidazole heterocycles. European Journal of Medicinal Chemistry. 44(5). 2202–2210. 34 indexed citations
19.
Gao, Weina, Dong‐Qing Wei, Yun Li, et al.. (2007). Agaritine and Its Derivatives Are Potential Inhibitors against HIV Proteases. Medicinal Chemistry. 3(3). 221–226. 48 indexed citations
20.
Mao, Jingyuan, et al.. (2003). [Clinical study on effect of shengmai injection on serum concentration and pharmacokinetic parameters of digoxin in patients with congestive heart failure].. PubMed. 23(5). 347–50. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raman Sharma Breakdown of academic impact, for papers by Maria Giovanna Chini Breakdown of academic impact, for papers by Valentina Sepe Breakdown of academic impact, for papers by Onat Kadioglu Breakdown of academic impact, for papers by Tatu Pantsar Breakdown of academic impact, for papers by Dennis Dean Breakdown of academic impact, for papers by Lushan Yu Breakdown of academic impact, for papers by Nan Ma Breakdown of academic impact, for papers by Karl‐Heinz Baringhaus
Rankless by CCL
2026